Scarica l'app Stockscreener
74.51
0.85%
-0.64
Dopo l'orario di chiusura:
73.90
-0.61
-0.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$75.15
Aprire:
$74.96
Volume 24 ore:
2.31M
Relative Volume:
1.01
Capitalizzazione di mercato:
$14.36B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-30.92
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
+0.36%
1M Prestazione:
+12.23%
6M Prestazione:
+87.31%
1 anno Prestazione:
+171.04%
Intervallo 1D:
$73.95
$75.61
Intervallo di 1 settimana:
$70.35
$75.61
Portata 52W:
$25.34
$75.61
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Confronta BBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
74.51 | 14.48B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Bernstein | Outperform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
BridgeBio Pharma (BBIO) Receives Maintained Rating with Raised P - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighTime to Buy? - MarketBeat
Is the Market Bullish or Bearish on BridgeBio Pharma Inc? - Benzinga
Castleark Management LLC Cuts Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Gilder Gagnon Howe & Co. LLC Boosts Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Eventide Asset Management LLC Decreases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha
BridgeBio Pharma stock hits all-time high at 75.13 USD - Investing.com
BridgeBio Pharma stock hits all-time high at 75.13 USD By Investing.com - Investing.com Australia
BridgeBio Pharma (BBIO) Valuation After Attruby-Driven Earnings Beat and Renewed Analyst Support - Yahoo Finance
What Recent Clinical Wins Mean For BridgeBio Pharma’s Evolving Growth Story - Yahoo Finance
Frontier Capital Management Co. LLC Sells 233,538 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bernstein initiates BridgeBio Pharma stock coverage with Outperform rating By Investing.com - Investing.com Canada
Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target - marketscreener.com
This Option Care Health Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - Benzinga
HighVista Strategies LLC Increases Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bernstein Initiates Coverage of BridgeBio Pharma (BBIO) with Outperform Recommendation - Nasdaq
BBIO Gets "Outperform" Rating as Bernstein Initiates Coverage | - GuruFocus
Federated Hermes Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio (BBIO) Unveils Promising Preclinical Data for Cancer T - GuruFocus
BridgeBio (BBIO) Unveils Promising Preclinical Data for Cancer Treatment - GuruFocus
Apuli Maricel, chief accounting officer, sells $148k in BridgeBio (BBIO) - Investing.com Canada
This Hot Biotech Stock Just Set New All-Time Highs - Barchart.com
BridgeBio Pharma (NASDAQ:BBIO) CAO Sells $148,520.00 in Stock - MarketBeat
Insider Sell Alert: Maricel Apuli Sells 2,000 Shares of BridgeBi - GuruFocus
Stempoint Capital LP Reduces Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Invesco Ltd. Has $120.95 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
89,312 Shares in BridgeBio Pharma, Inc. $BBIO Acquired by WINTON GROUP Ltd - MarketBeat
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
BridgeBio Pharma CEO Kumar sells $5.9 million in BBIO stock By Investing.com - Investing.com Canada
Bridgebio Pharma Insider Sold Shares Worth $5,908,476, According to a Recent SEC Filing - marketscreener.com
Price-Driven Insight from (BBIO) for Rule-Based Strategy - news.stocktradersdaily.com
BridgeBio Pharma, Inc. $BBIO Holdings Lifted by Bosun Asset Management LLC - MarketBeat
Tema Etfs LLC Sells 25,530 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Edgestream Partners L.P. Makes New $1.92 Million Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO Position Cut by Affinity Asset Advisors LLC - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Norges Bank Purchases New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Lymphatic Malformations Market Expected to Experience Major - openPR.com
Legal & General Group Plc Purchases 23,716 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Panagora Asset Management Inc. Boosts Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
72,047 Shares in BridgeBio Pharma, Inc. $BBIO Acquired by Capital Fund Management S.A. - MarketBeat
Rhumbline Advisers Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
How BridgeBio Pharma Inc. stock valuations compare to rivalsMarket Activity Recap & Free Fast Gain Swing Trade Alerts - Newser
BridgeBio Pharma stock hits 52-week high at $72.36 By Investing.com - Investing.com South Africa
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighWhat's Next? - MarketBeat
BridgeBio Pharma stock hits 52-week high at $72.36 - Investing.com
What valuation multiples suggest for BridgeBio Pharma Inc. stockJuly 2025 EndofMonth & Accurate Entry and Exit Point Alerts - Newser
Prudential Financial Inc. Has $5.07 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
What dividend safety score for BridgeBio Pharma Inc. stockJuly 2025 Reactions & High Yield Stock Recommendations - Newser
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):